Harbour BioMed Enters Multi-Year HCAb Technology Licensing Agreement with a Top-Ten Global Pharma for Next Generation Human Antibody Discovery

Technology produces novel heavy chain-only antibodies for
bi-specific, single domain antibodies or CAR-Ts

CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands, & SHANGHAI–(BUSINESS WIRE)–Harbour BioMed today announced a worldwide multi-year license agreement
with a Top-Ten, global pharmaceutical leader in immunology and
immuno-oncology to discover, develop, and commercialize biologic
therapeutics using Harbour’s patented HCAb transgenic mouse platform.
The HCAb platform generates novel, fully human heavy chain only
antibodies to accelerate the discovery and development of advanced
biologic therapeutics, especially single domain antibodies, bi-specific
and multi-specific antibodies, and CAR-Ts.

“Drug discovery in the burgeoning fields of immuno-oncology and
immunotherapy is relying increasingly on advanced biological approaches
to selectively attack one or more immune targets and modulate the immune
system to treat cancer and other diseases,” said Dr. Jingsong Wang, CEO
of Harbour BioMed. “The HCAb platform is emerging as a powerful
technology to enable next generation biologic discovery for our internal
portfolio and a select group of licensing partners. This new license
agreement, with one of the world’s leading pharmaceutical companies, is
a significant endorsement of our approach.”

Under the terms of the agreement, Harbour BioMed will receive an upfront
payment and will be further eligible to receive a combination of
development and sales related milestone payments and royalties. Specific
financial details were not disclosed. Harbour BioMed signed the
non-exclusive license through its wholly-owned subsidiary, Harbour
Antibodies HCAb BV.

About Harbour BioMed
Harbour BioMed is a global
biopharmaceutical company developing innovative therapeutics in the
fields of Immuno-Oncology and Inflammatory Diseases. The company’s
discovery and development programs are centered around its two patented
transgenic mouse platforms (Harbour Mice™) for generating fully human
monoclonal antibodies. The company is building its proprietary pipeline
through internal discovery research, collaboration with co-discovery and
co-development partners, and acquisition of innovative preclinical and
clinical stage assets that strategically fit its internal portfolio. For
more information, visit www.harbourbiomed.com.

About Harbour Mice™ Technology
Harbour Mice™ technology
consists of two fully human transgenic mouse platforms that can produce
both full-length human IgG molecules (H2L2) and heavy chain only human
IgG molecules (HCAb). The Harbour Mice™ technology is owned by Harbour
Antibodies H2L2 BV and Harbour Antibodies HCAb BV, which are
subsidiaries of Harbour BioMed.

Contacts

Jung Lee
Harbour Antibodies
(857) 214-0976
[email protected]